PPIDT00142

Drug Information
NameGlatiramer
SequenceEAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK
DrugBank_IDDB05259
Typebiotech
IndicationGlatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[L41940]
Dosage Forms
Form Route Strength
Solution Subcutaneous
2000000 mg
Injection, solution Parenteral
20 mg/ml
Injection, solution Parenteral
40 mg/ml
Injection Subcutaneous
20 mg/1mL
Injection, powder, for solution Subcutaneous
20 mg/ml
Injection, solution Subcutaneous
20 mg/1mL
Injection, solution Subcutaneous
40 MG/ML
Injection, solution Subcutaneous
40 mg/1mL
Powder, for solution Subcutaneous
20 mg / vial
Solution Parenteral
40.000 mg
Solution Subcutaneous
20 mg / mL
Solution Subcutaneous
40 mg / mL
Injection, solution Parenteral
Solution Subcutaneous
3600000 mg
Injection, solution Subcutaneous
20 MG/ML
Solution Subcutaneous
20.000 mg
Solution Subcutaneous
4000000 mg
Injection, solution —
Injection, solution Subcutaneous
Solution Subcutaneous
20.00 mg
Solution —
20.000 mg
Injection, solution —
20 mg/ml
Injection, solution —
40 mg/ml
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
No target records.